{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:03:17Z","timestamp":1784361797283,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ahjo.2026.100822","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:51:34Z","timestamp":1783093894000},"page":"100822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Shreyas","family":"Nandyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviral","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revati","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Caputi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Odoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukriti","family":"Banthiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saketh","family":"Vinjamuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0005","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ahjo.2026.100822_bb0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.ahjo.2026.100822_bb0015","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ahjo.2026.100822_bb0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100822_bb0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ahjo.2026.100822_bb0035","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.cardfail.2023.08.017","article-title":"Novel recommendations for the treatment of patients with heart failure: 2023 focused update of the 2021 ESC heart failure guidelines","volume":"29","author":"Voors","year":"2023","journal-title":"J. Card. Fail."},{"issue":"Suppl. 1","key":"10.1016\/j.ahjo.2026.100822_bb0040","doi-asserted-by":"crossref","first-page":"i137","DOI":"10.1093\/eurheartjsupp\/suae117","article-title":"SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting","volume":"27","author":"Merlo","year":"2025","journal-title":"Eur. Heart J. Suppl. J. Eur. Soc. Cardiol."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100822_bb0045","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am. J. Med."},{"issue":"24","key":"10.1016\/j.ahjo.2026.100822_bb0050","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"10.1016\/j.ahjo.2026.100822_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100822_bb0060","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.ahjo.2026.100822_bb0065","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","article-title":"Safety and efficacy of SGLT2 inhibitors for amyloid light-chain cardiomyopathy","volume":"30","author":"Lang","year":"2024","journal-title":"J. Card. Fail."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ahjo.2026.100822_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy","volume":"243","author":"Byer","year":"2025","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0080","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ahjo.2026.100822_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors - do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol. Metab."},{"issue":"8","key":"10.1016\/j.ahjo.2026.100822_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082150","article-title":"Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis","volume":"10","author":"Masson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ahjo.2026.100822_bb0100","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.hlc.2022.06.286","article-title":"SGLT2 inhibitors reduce epicardial adipose tissue: a meta-analysis","volume":"31","author":"Kalman","year":"2022","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ahjo.2026.100822_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"37","key":"10.1016\/j.ahjo.2026.100822_bb0115","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ahjo.2026.100822_bb0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ahjo.2026.100822_bb0125","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100822_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","article-title":"SGLT2 inhibitor: not a traditional diuretic for heart failure","volume":"32","author":"Verma","year":"2020","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.ahjo.2026.100822_bb0135","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:32:13Z","timestamp":1784359933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S2666602226001102"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100822","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100822"}}